Efavirenz

證據等級: L5

預測適應症: 3 個

Efavirenz: From HIV-1 Infection to Simian Immunodeficiency Virus Infection

One-Sentence Summary

Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) established for HIV-1 infection. The TxGNN model predicts a 99.80% score for “Simian Immunodeficiency Virus (SIV) Infection” as a new indication, but the supporting evidence — 1 clinical trial (unrelated drug, withdrawn) and 16 publications — consists entirely of preclinical animal-model research, not evidence of treating a distinct human disease.

Quick Overview

Item	Content
Original Indication	HIV-1 infection (established antiretroviral use; not extractable from South African regulatory data below, see Market Status)
Predicted New Indication	Simian immunodeficiency virus infection
TxGNN Prediction Score	99.80%
Evidence Level	L4 (preclinical/animal-model studies only; no relevant completed human RCT)
South Africa Market Status	Not marketed
Number of SAHPRA Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is currently not available in the evidence pack (Data Gap DG002). Based on known pharmacology, efavirenz is an NNRTI that binds an allosteric pocket on HIV-1 reverse transcriptase (RT), a mechanism specific to the HIV-1 enzyme structure.

Critically, the predicted “new indication” here is not a distinct human disease — it is simian immunodeficiency virus (SIV) infection, the primate counterpart of HIV. Wild-type SIV RT is naturally not sensitive to NNRTIs like efavirenz because its binding pocket differs structurally from HIV-1 RT. The literature evidence base consists of studies using an artificially engineered “RT-SHIV” chimeric virus, in which researchers replaced SIV’s own RT with HIV-1 RT specifically so that NNRTI-based regimens (including efavirenz) could be tested in a macaque model of HIV/AIDS. This is a research-tool model built to study human HIV pathophysiology and drug resistance in animals — it is not evidence that efavirenz treats naturally occurring SIV infection in its own right.

In other words, the TxGNN model has likely picked up on efavirenz’s known antiretroviral mechanism and associated it with a taxonomically adjacent viral disease label, rather than identifying a genuinely novel indication outside the drug’s existing pharmacological class.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00863668	NA	Withdrawn	0	Studied decay kinetics of HIV/SIV using the integrase inhibitor raltegravir, not efavirenz; trial withdrawn with zero enrollment. Relevance graded C — different drug class, no usable data.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
35856680	2022	Imaging/pharmacology study	Antimicrob Agents Chemother	Mass spectrometry imaging of antiretroviral distribution and viral RNA in spleens of ART-treated nonhuman primates
24777106	2014	Animal model study	Antimicrob Agents Chemother	Enhanced 4/5-drug HAART regimens improved RT-SHIV viral decay kinetics in rhesus macaques
22933296	2012	Animal model/virology	J Virol	Allele-specific PCR detection of pre-existing drug-resistant RT-SHIV variants in macaques
21084490	2011	Virology/sequence analysis	J Virol	Genetic diversity of RT-SHIV persists in macaques despite antiretroviral therapy, including short-course efavirenz monotherapy
21289110	2011	Basic virology	J Virol	Mechanistic study of HIV-1/SIV Gag-Pol interaction with clathrin; not a treatment study
19889213	2009	Animal model study	Retrovirology	RT-SHIV subpopulation dynamics in macaques during short-course efavirenz monotherapy followed by combination ART
19195672	2009	Animal model study	Virology	Vaginal transmission characterization of RT-SHIV in Chinese rhesus macaques
15919889	2005	Animal model study	J Virol	HAART regimen (efavirenz + lamivudine + tenofovir) suppressed viral load in RT-SHIV-infected rhesus macaques
15328115	2004	Animal model study	Antimicrob Agents Chemother	Evaluated efavirenz antiviral activity specifically in the RT-SHIV chimeric macaque model (engineered for NNRTI susceptibility)
15564466	2004	In vitro virology	J Virol	In vitro characterization of the RT-SHIV chimera used to study antiviral resistance in pigtail macaques

Note: all listed studies are preclinical (tier 3, animal/in vitro models). None constitute clinical evidence in humans or naturally SIV-infected animals.

South Africa Market Information

Efavirenz currently has no SAHPRA registration records in this evidence pack (0 registrations; market status: not marketed). No product-level licence data is available to summarise.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

(Key warnings, contraindications, and drug interaction data are marked as data gaps in the evidence pack — DG001, severity Blocking — and could not be summarised here.)

Conclusion and Next Steps

Decision: Hold

Rationale:

The only clinical trial identified is for a different drug (raltegravir) and was withdrawn with zero enrollment; it provides no support for this indication.
All 16 literature references are preclinical animal studies using an engineered RT-SHIV chimeric virus — a research tool designed to make SIV artificially susceptible to NNRTIs like efavirenz, not evidence that efavirenz treats naturally occurring SIV infection.
SAHPRA safety data (PI warnings, contraindications, drug interactions) is entirely unavailable (DG001, Blocking severity) and mechanism-of-action documentation is missing (DG002), so this candidate cannot pass an initial safety screen (S1).
Efavirenz is not currently marketed in South Africa (0 SAHPRA registrations).

To proceed, the following is needed:

SAHPRA-approved PI (warnings, contraindications, drug interactions) to clear the Blocking data gap
Confirmed mechanism-of-action documentation from DrugBank or equivalent source
Evidence of clinical relevance to an actual human/veterinary disease population, since the current “new indication” largely reflects a taxonomic variant of efavirenz’s existing approved use rather than a distinct disease
SAHPRA market authorisation status confirmation if commercial availability in South Africa is being considered

Note: two additional TxGNN-predicted indications for efavirenz (feline immunodeficiency virus infection, and a rare genetic neurodevelopmental disorder) were also reviewed and carry even weaker evidence (Evidence Level L5 — model prediction only, with no or minimally relevant supporting studies); both are also recommended Hold.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.